Close Menu

leukemia

Buoyed by a string of positive news, the San Diego firm's stock was up 22 percent in Friday afternoon trading and 80 percent from last week.

Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.

Since the commercial launch of its technology last year, the firm has been validating it in studies with academic groups and pharmaceutical companies.

In Genome Biology this week: relapse-linked mutations in T cell acute lymphoblastic leukemia, single-cell atlas of human tissue transcriptomes, and more.

In a retrospective analysis, ALL patients tested with NGS were less likely to achieve MRD-negative status than when tested with flow cytometry.

Increased incidental detection of clonal hematopoiesis and new considerations for mutations in myelodysplastic precursors herald improved precision medicine strategies.

The firm's new application of its BCR-ABL test will be able to detect p190 transcripts and is currently for research use only.

Novitas added multiple leukemia biomarkers to its coverage determination, as well as the ThyGeNEXT molecular panel.

For the quarter ended Sept. 30, the company reported $2.2 million in revenues, down from $3.3 million in Q3 of 2019 but beating the average Wall Street estimate.

Researchers combined protein expression with mutational analysis to map the somatic genotype and clonal architecture of AML with its immunophenotype.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.